2076975 2077203
최종편집 2022-07-04 17:00 (월)
Global big pharma grows its sales amid the spread of COVID-19
상태바
Global big pharma grows its sales amid the spread of COVID-19
  • Hyeokgi Lee, Newsmp
  • 승인 2022.05.13 17:44
  • 댓글 0
이 기사를 공유합니다

Moderna 213.2%ㆍPfizer 76.8%ㆍAstraZeneca 55.6%ㆍMSD 49.6%
GSKㆍNovo NordiskㆍLillyㆍSanofiㆍRoche ↑ double-digit as well

[Newsmp] Major global big pharmaceutical companies expanded their sales significantly in the first quarter while the Omicron variant prevailed worldwide.

In particular, the growth of companies with COVID-19 treatments or vaccines such as Pfizer, Moderna, AstraZeneca, and MSD was remarkable.

The company that showed the most growth rate was Moderna, which recorded sales of about KRW 7.75 trillion in the first quarter, a growth rate of 213.2% compared to the same period of the previous year (based on the exchange rate on the 9th).

Sales of the COVID-19 vaccine (Spikevax) alone reached KRW 7.5 trillion. The figure is similar to the total sales recorded by Novo Nordisk during the same period, and Moderna joined big pharma with this vaccine.

Pfizer, led by the COVID-19 vaccine Comirnaty and oral treatment Paxlovid, achieved sales of KRW 32.7819 trillion with a growth rate of 76.8%, surpassing Johnson & Johnson, which posted KRW 30 trillion in sales including medical devices.

In the first quarter, Comirnaty’s sales alone amounted to KRW 16.9 trillion, accounting for more than half of Pfizer’s total sales, and Paxlovid also contributed nearly KRW 2 trillion in new sales.

AstraZeneca also achieved sales growth of more than 50% with the COVID-19 vaccine Vaxzevria and antibody treatment Evusheld.

MSD, which generated KRW 4.15 trillion in new sales by Lagevrio, an oral COVID-19 treatment, also grew nearly 50%, with quarterly sales exceeding KRW 20 trillion in the first quarter from KRW 13.6 trillion in the first quarter of last year.

GSK gained a growth rate of close to 30% as its COVID-19 antibody treatment Xevudy generated new sales of KRW 2.2 trillion and expanded its sales to KRW 3.3 trillion.

Moreover, Lilly and Roche also recorded double-digit growth rates with the COVID-19 antibody treatments.

In the meantime, Gilead Sciences remained at a 2.6% growth rate as the growth of Veklury, the first COVID-19 treatment, slowed, and Johnson & Johnson’s sales growth remained at 5.0% due to only KRW 600 billion in sales despite the growth of vaccines.

Furthermore, as the U.S. Food and Drug Administration recently restricted the use of Johnson & Johnson’s vaccine, it seems unlikely that it will contribute to Johnson & Johnson’s growth.

Among big pharma without COVID-19 related products, Novo Nordisk’s growth rate stood out the most at 24.3%, and Sanofi also achieved double-digit growth.

In addition, Amgen and BMS remained in the 5% mark, AbbVie and Organon in the 4% mark, and Novartis in the 1% mark, while the sales of Biogen and Viatris decreased by 5~6%, showing significant differences in growth rates depending on whether they have COVID-19 related products.

Meanwhile, big pharma, whose sales have surged due to COVID-19, showed a relatively reduced R&D intensity.

Moderna, whose quarterly sales tripled, saw its R&D intensity plunge to 9.1%, while MSD also fell 6.5%p from 22.7% to 16.2%.

AstraZeneca also lost 4.7%p from 23.4% to 18.7%, and Pfizer fell 4.4%p from 13.7% to single-digit.

Lilly was reduced by 4.0%p from 24.6% to 20.6%, but maintained the 20% mark, while GSK fell 3.2%p from 15.1% to 11.9%, but kept double-digit.

On the other hand, Biogen rose 2.7%p from 19.1% to 21.8%, reaching the 20% mark, while the R&D intensity of Organon, Gilead Sciences, and AbbVie expanded by more than 1.0%.


댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.